• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Pandion Therapeutics Appoints Katina Dorton to its Board of Directors

    12/3/20 8:00:00 AM ET
    $PAND
    $ECOL
    $MS
    $FULC
    Environmental Services
    Public Utilities
    Investment Bankers/Brokers/Service
    Finance
    Get the next $PAND alert in real time by email

    WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the appointment of Katina Dorton, J.D., M.B.A., to Pandion’s board of directors and as chair of the audit committee. Ms. Dorton assumes the position of chair of the audit committee from Christopher Fuglesang, Ph.D., J.D., who will continue to serve as a member of the board and audit committee. Mitchell Mutz, Ph.D., resigned from the Company’s board on December 2, 2020.

    “Ms. Dorton brings to Pandion over two decades of financial expertise, leading a multitude of financial transactions for companies in the life sciences industry. We look forward to her contributions to the growth and value creation for Pandion as a newly public company,” said Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics. “We also sincerely thank Mitchell for his guidance as we brought Pandion from an idea through its first-in-human clinical trial and wish him the best in his future endeavors.”

    “Pandion has the potential to bring about the next generation in autoimmune treatments with a unique focus on activating the body’s natural immune control nodes. I am excited to be a part of the team, particularly as we look to the Phase 1a results for the Company’s lead program, PT101, in early 2021,” commented Katina Dorton.

    Ms. Dorton currently serves on the board of directors for Fulcrum Therapeutics (Nasdaq: FULC) and US Ecology (Nasdaq: ECOL). She most recently served as Chief Financial Officer of Repare Therapeutics, a synthetic lethality and DNA repair-focused oncology company. Prior to Repare, Ms. Dorton served as Chief Financial Officer of AVROBIO, a lentiviral gene therapy company. Earlier in her career, she served as a managing director in investment banking for Morgan Stanley and Needham & Company and as an associate attorney at Sullivan & Cromwell. Ms. Dorton received her J.D. from the University of Virginia School of Law, her M.B.A. from George Washington University and her B.A. from Duke University.

    About Pandion Therapeutics
    Pandion Therapeutics is developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion’s TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform enables the company to create a pipeline of product candidates using immunomodulatory effector modules, with the ability to also combine an effector module with a tissue-targeted tether module in a bifunctional format. Pandion’s lead product candidate PT101, a combination of an interleukin-2 mutein effector module with a protein backbone, is designed to selectively expand regulatory T cells systemically, without activating proinflammatory cells, such as conventional T cells and natural killer cells, is currently in a Phase 1a clinical trial. Pandion is continuing to develop and expand its library of effector and tether modules as part of its earlier-stage research and discovery pipeline. For more information, please visit www.pandiontx.com.

    Forward-Looking Statements
    This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company’s strategy and clinical development plans, timelines and prospects, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with Pandion’s ability to obtain and maintain necessary approvals from the FDA and other regulatory authorities; initiate preclinical studies and clinical trials of PT101 and its other product candidates; advance PT101 and its other product candidates in preclinical research and clinical trials; replicate in clinical trials positive results found in preclinical studies; advance the development of its product candidates under the timelines it anticipates in current and future clinical trials; obtain, maintain or protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

    Contacts

    Media:
    Kathryn Morris
    The Yates Network
    914-204-6412
    [email protected]

    Investors:
    Michelle Avery
    Pandion Therapeutics
    857-273-0444
    [email protected]


    Get the next $PAND alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PAND
    $ECOL
    $MS
    $FULC

    CompanyDatePrice TargetRatingAnalyst
    Morgan Stanley
    $MS
    7/9/2025$160.00Mkt Perform → Outperform
    Keefe Bruyette
    Fulcrum Therapeutics Inc.
    $FULC
    5/23/2025$12.00Market Perform → Outperform
    Leerink Partners
    Fulcrum Therapeutics Inc.
    $FULC
    5/15/2025$10.00Neutral → Overweight
    Cantor Fitzgerald
    Morgan Stanley
    $MS
    11/26/2024Buy → Hold
    HSBC Securities
    Morgan Stanley
    $MS
    11/15/2024$142.00Underweight → Equal Weight
    Wells Fargo
    Morgan Stanley
    $MS
    10/4/2024$118.00Hold → Buy
    HSBC Securities
    Fulcrum Therapeutics Inc.
    $FULC
    9/13/2024$17.00 → $4.00Buy → Neutral
    H.C. Wainwright
    Fulcrum Therapeutics Inc.
    $FULC
    9/12/2024$15.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $PAND
    $ECOL
    $MS
    $FULC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Morgan Stanley Wealth Management Delivers New Tool to Help Clients Tackle Single Stock Risk

      Morgan Stanley Wealth Management's Global Investment Office (GIO) has launched the Equity Vulnerability Score, a proprietary tool that can help clients and the Financial Advisors who serve them measure and rank the susceptibility of US stocks to potential future drops in value. As a risk management tool, this can help provide important insights for investors—especially those who hold concentrated equity positions, which Morgan Stanley defines as five or fewer stocks making up more than 30% of the risk in a portfolio. Concentrated equity positions often occur naturally for company founders, those who receive equity compensation, and early investors. As these positions grow over time, they

      7/24/25 10:30:00 AM ET
      $MS
      Investment Bankers/Brokers/Service
      Finance
    • E*TRADE from Morgan Stanley Raises the Bar for Active Trader Experience with New Desktop Platform: Power E*TRADE Pro

      Power E*TRADE Pro delivers industry-leading customization features for multi-monitor traders, boasting robust views of market depth, over 120 technical studies, and window linking to analyze symbols across multiple charts at once. The new desktop platform adds to E*TRADE's suite of web and mobile-based trading platforms, including etrade.com, Power E*TRADE web, and the E*TRADE and Power E*TRADE mobile apps. E*TRADE from Morgan Stanley today announced the launch of Power E*TRADE Pro. The new desktop platform is designed to meet the discerning needs of active traders, offering a high level of customization, along with sophisticated tools powered by an advanced modern architecture. This p

      7/21/25 9:00:00 AM ET
      $MS
      Investment Bankers/Brokers/Service
      Finance
    • Long-Term Incentive Plans on the Rise: Morgan Stanley 2025 Single Family Office Compensation Report

      Morgan Stanley's Single Family Office Advisory today released its biennial compensation report. The 2025 report, created in collaboration with Botoff Consulting, offers critical benchmarks and trend analysis to empower family office leaders to make informed staffing and compensation decisions. Findings spotlight how investment-focused single family offices diverge from broader single family office trends, particularly in terms of compensation. Investment-focused single family offices are prioritizing the alignment of compensation practices with organizational strategy and AUM, especially through executive compensation and structured long-term incentive (LTI) plans. LTIs are increasingly b

      7/17/25 10:00:00 AM ET
      $MS
      Investment Bankers/Brokers/Service
      Finance

    $PAND
    $ECOL
    $MS
    $FULC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sapir Alex bought $492,028 worth of shares (43,360 units at $11.35) (SEC Form 4)

      4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

      3/5/24 4:15:17 PM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PAND
    $ECOL
    $MS
    $FULC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Yeshaya Sharon sold $3,576,706 worth of shares (25,583 units at $139.81) (SEC Form 4)

      4 - MORGAN STANLEY (0000895421) (Issuer)

      7/18/25 4:13:37 PM ET
      $MS
      Investment Bankers/Brokers/Service
      Finance
    • Chief Risk Officer Smith Charles A sold $2,805,918 worth of shares (20,000 units at $140.30), decreasing direct ownership by 14% to 119,239 units (SEC Form 4)

      4 - MORGAN STANLEY (0000895421) (Issuer)

      7/18/25 4:12:10 PM ET
      $MS
      Investment Bankers/Brokers/Service
      Finance
    • Co-President Simkowitz Daniel A sold $4,092,628 worth of shares (29,000 units at $141.13) and gifted 7,559 shares, decreasing direct ownership by 9% to 391,546 units (SEC Form 4)

      4 - MORGAN STANLEY (0000895421) (Issuer)

      7/18/25 4:11:24 PM ET
      $MS
      Investment Bankers/Brokers/Service
      Finance

    $PAND
    $ECOL
    $MS
    $FULC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley upgraded by Keefe Bruyette with a new price target

      Keefe Bruyette upgraded Morgan Stanley from Mkt Perform to Outperform and set a new price target of $160.00

      7/9/25 8:15:27 AM ET
      $MS
      Investment Bankers/Brokers/Service
      Finance
    • Fulcrum Therapeutics upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Fulcrum Therapeutics from Market Perform to Outperform and set a new price target of $12.00

      5/23/25 8:13:14 AM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fulcrum Therapeutics upgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald upgraded Fulcrum Therapeutics from Neutral to Overweight and set a new price target of $10.00

      5/15/25 8:05:44 AM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PAND
    $ECOL
    $MS
    $FULC
    SEC Filings

    See more
    • SEC Form FWP filed by Morgan Stanley

      FWP - MORGAN STANLEY (0000895421) (Subject)

      7/25/25 4:54:28 PM ET
      $MS
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form FWP filed by Morgan Stanley

      FWP - MORGAN STANLEY (0000895421) (Subject)

      7/25/25 2:56:55 PM ET
      $MS
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form FWP filed by Morgan Stanley

      FWP - MORGAN STANLEY (0000895421) (Subject)

      7/25/25 2:55:49 PM ET
      $MS
      Investment Bankers/Brokers/Service
      Finance

    $PAND
    $ECOL
    $MS
    $FULC
    Leadership Updates

    Live Leadership Updates

    See more
    • Morgan Stanley Appoints 173 New Managing Directors

      Morgan Stanley has announced the appointment of 173 Managing Directors. The new Managing Directors are: Andrea Alberti Jon LeBoutillier Andrew Arena Ben L. Lee Emma Atkins Dick Lee Mona Benisi Jason Lees Maria Berezhkova Benjamin Liberos Alison Bilger Uri Lichtenfeld Priya Bindra Daniel J. Lingeza Nathan Bishop Fan Liu Peter Boehm Sarah Lloyd-Johns Dan Bray Elly Lukenskaite Katalin Broz Mayank Maheshwari Shinya Bukawa Richard Mancusi Edward Bury Koren Maranca Ryuk Byun Lesley A. Matthews James Carroll Helen Mbugua-Kahuki Matt Cashia Mandy McClung Kendal Cehanowicz Felipe M

      1/10/25 9:00:00 AM ET
      $MS
      Investment Bankers/Brokers/Service
      Finance
    • Morgan Stanley Investment Management's 1GT Participates in €115 Million Investment in XOCEAN

      Funding to help accelerate growth of its ocean data services platform Morgan Stanley Investment Management (MSIM) announced today that the 1GT private climate equity strategy (1GT) participated in a €115 million fundraise for XOCEAN (company), a leading provider of ocean data to the offshore energy and civil hydrography sectors. 1GT participated in an investor consortium that includes S2G Ventures (S2G), Climate Investment (CI), and Crown Family's CC Industries (CCI). The investor consortium brings fit-for-purpose capital, diverse operational experience across the offshore value chain, and the strategic connectivity to accelerate the growth of XOCEAN's platform to meet the rapidly growi

      1/9/25 2:32:00 PM ET
      $MS
      Investment Bankers/Brokers/Service
      Finance
    • Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

      CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Isabel Kalofonos as chief commercial officer and Heather Faulds as chief regulatory affairs & quality assurance officer. Together, Ms. Kalofonos and Ms. Faulds will be instrumental in advancing losmapimod towards a New Drug Application (NDA) submission and preparing for commercial launch. "I am excited to welcome Isabel to our leadership team as we continue to advance towards the potential approval a

      8/19/24 7:00:00 AM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PAND
    $ECOL
    $MS
    $FULC
    Financials

    Live finance-specific insights

    See more
    • Morgan Stanley Reports Second Quarter 2025 Earnings Results

      Morgan Stanley (NYSE:MS) today announced its second quarter 2025 financial results. The financial results are now available on the Firm's Investor Relations website at www.morganstanley.com/about-us-ir/earnings-releases and will be available on a Form 8-K filed with the Securities and Exchange Commission (SEC) on July 16, 2025, and available on the SEC's website at www.sec.gov. A conference call to discuss the results will be held today at 8:30 a.m. (ET). The call will be available at www.morganstanley.com or by dialing 1-866-431-2040 (domestic) and 1-929-477-0541 (international); the passcode is 400700. Playback will be available via webcast on our website. Morgan Stanley is a leading

      7/16/25 7:27:00 AM ET
      $MS
      Investment Bankers/Brokers/Service
      Finance
    • Morgan Stanley Announces 7.5 Cents Dividend Increase and Authorization of a Renewed $20 Billion Multi-Year Common Equity Share Repurchase Program

      Morgan Stanley (NYSE:MS) announced that it will increase its quarterly common stock dividend to $1.00 per share from the current $0.925 per share, beginning with the common stock dividend expected to be declared by the Firm's Board of Directors in the third quarter of 2025. In addition, the Firm's Board of Directors reauthorized a multi-year common equity share repurchase program of up to $20 billion, without a set expiration date, beginning in the third quarter of 2025. The share repurchases will be exercised from time to time at prices the Firm deems appropriate, subject to various considerations, including current market conditions, the Firm's capital position and future economic and e

      7/1/25 4:36:00 PM ET
      $MS
      Investment Bankers/Brokers/Service
      Finance
    • Eaton Vance Closed-End Funds Release Estimated Sources of Distributions

      The Eaton Vance closed-end funds listed below released today the estimated sources of their June distributions (each a "Fund"). This press release is issued as required by the Funds' managed distribution plan (Plan) and an exemptive order received from the U.S. Securities and Exchange Commission. The Board of Trustees has approved the implementation of the Plan to make monthly, as noted below, cash distributions to common shareholders, stated in terms of a fixed amount per common share. This information is sent to you for informational purposes only and is an estimate of the sources of the June distribution. It is not determinative of the tax character of a Fund's distributions for the 2025

      6/30/25 4:00:00 PM ET
      $EOI
      $EOS
      $ETB
      $ETG
      Finance/Investors Services
      Finance
      Trusts Except Educational Religious and Charitable
      Investment Bankers/Brokers/Service

    $PAND
    $ECOL
    $MS
    $FULC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

      SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

      11/14/24 4:25:46 PM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

      SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

      11/14/24 6:15:07 AM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

      SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

      11/12/24 3:51:00 PM ET
      $FULC
      Biotechnology: Pharmaceutical Preparations
      Health Care